TCF12 Mouse Monoclonal Antibody
- Known as:
- TCF12 Mouse Monoclonal Antibody
- Catalog number:
- ENZ-006938-M01
- Product Quantity:
- 0.1mg
- Category:
- -
- Supplier:
- Zyagen
- Gene target:
- TCF12 Mouse Monoclonal Antibody
Related genes to: TCF12 Mouse Monoclonal Antibody
- Gene:
- TCF12 NIH gene
- Name:
- transcription factor 12
- Previous symbol:
- -
- Synonyms:
- HEB, HTF4, HsT17266, bHLHb20, p64
- Chromosome:
- 15q21.3
- Locus Type:
- gene with protein product
- Date approved:
- 1994-06-17
- Date modifiied:
- 2018-02-20
Related products to: TCF12 Mouse Monoclonal Antibody
Related articles to: TCF12 Mouse Monoclonal Antibody
- Gene-based rare variant analyses often lack statistical power and may overlook transcript-specific effects. Here, we present a transcript-aware aggregation framework. In simulation studies, the framework maintains appropriate false-positive rates and shows competitive power relative to standard single-transcript analyses, approaching the performance of the ideal case of knowing the most informative transcript in advance. We then apply the approach to 129 cardiopulmonary traits in over 240,000 whole-genome-sequenced All of Us participants. By leveraging transcript-specific annotations, we identify 11 novel associations and recover 47 reported associations, including potentially pleiotropic genes linked to plasma lipid traits (PPARG) and body habitus (TCF12). Notably, for TTN, a gene known for its transcript-specific effects in cardiomyopathy, our framework strengthens the association signal and pinpoints the N2B isoform, which shows a stronger association with cardiomyopathy than other transcripts. These findings highlight the value of a transcript-aware framework for improving rare variant association studies. - Source: PubMed
Publication date: 2026/07/24
Zhang JingwenHong So-HyeonWang XinJurgens Sean JLiu Ching-TiDupuis JoséeEllinor Patrick TO'Connor George TMei QuanshunChoi Seung Hoan - The traditional distinction between syndromic and nonsyndromic craniosynostosis has guided clinical management, but recent genomic advances suggest these categories represent a continuous spectrum rather than discrete entities. Data on genetic etiologies and long-term neurodevelopmental outcomes in Asian populations remain limited. - Source: PubMed
Publication date: 2026/08/17
Joo SunyoungKang Jeon-WoongYang Si WonJang Dae-HyunKim Jaewon - Transcription factor 12 (TCF12) is a basic helix-loop-helix transcription factor implicated in tissue differentiation and pathogenesis in many types of cancer. Its role in breast and ovarian cancer remains poorly understood. TCF12 protein expression was assessed by immunohistochemistry in 1,514 primary breast tumours and 423 ovarian tumours. TCF12 mRNA expression was analysed in the Molecular Taxonomy of Breast Cancer International Consortium cohort (n=1,980). Associations between protein expression with clinicopathological variables and patient survival were evaluated. In breast cancer, TCF12 was predominantly expressed in the nucleus with low nuclear expression observed in 32% of cases. Both TCF12 protein and mRNA expression were significantly associated with adverse clinicopathological features, including larger tumour size, higher Nottingham Prognostic Index category, and oestrogen receptor-negative tumours. Low nuclear TCF12 expression was associated with adverse breast cancer-specific survival, particularly in oestrogen receptor-positive tumours; it remained an independent adverse prognostic factor in the multivariate analysis. Similar findings were observed when assessing TCF12 mRNA. No association was observed between TCF12 expression and survival of ovarian cancer patients. Low TCF12 expression identified a biologically aggressive subset of breast cancers with poor prognosis. These findings highlight the potential of TCF12 as a prognostic biomarker in breast cancer. No association between TCF12 expression and survival was observed in ovarian cancer patients, suggesting tumour-specific roles. - Source: PubMed
Publication date: 2026/08/04
Polchai NuanphanNdeke DenysAlshammari KhalidGreener Megan RMarak Tangkam RHenman MaisieDeen SuhaGreen Andrew REllis Ian ORakha Emad AMartin Stewart GStorr Sarah J - The genetic dissection of complex traits in livestock continues to pose a significant challenge in the field of animal genetics and breeding. Although traditional genome-wide association studies (GWAS) are capable of localizing genetic variants associated with specific traits, they are insufficient to elucidate the underlying physiological mechanisms. An integrated analysis of multi-trait GWAS and multi-transcriptomic data systematically identifies key tissues and cell types influencing complex traits in beef cattle and elucidates their genetic regulatory basis. - Source: PubMed
Publication date: 2026/07/28
Zhang BoyuQiu ShiyuanDu ZhenweiXiao HaoSu YingxiaoTang AnyiBao BinwuZhu BoChen YanGao XueXu LingyangWang ZezhaoZhang LupeiGao HuijiangLi JunyaZheng Caihong - Therapeutic resistance to trastuzumab remains a critical limitation in the management of HER2-positive (HER2+) breast cancer. Emerging evidence implicates epigenetic regulators, including microRNAs and histone demethylases, in modulating HER2 signaling and drug responsiveness. This study aimed to investigate the mechanistic role of miR-770-5p and its interplay with KDM5B in the context of trastuzumab resistance. An integrative approach combining in silico analyses with in vitro functional assays was employed in trastuzumab-sensitive and -resistant HER2 + breast cancer cell lines. Molecular, subcellular, and phenotypic effects of miR-770-5p modulation were assessed using qRT-PCR, Western blotting, immunofluorescence, RNA-FISH, luciferase reporter assays, and live-cell imaging. KDM5B was significantly overexpressed in HER2 + tumors and inversely correlated with HER2 expression. miR-770-5p directly targeted KDM5B and was associated with coordinated regulation of HER2 signaling at both transcription-associated and post-transcriptional levels. Overexpression of miR-770-5p was associated with reduced expression of KDM5B, TCF12, and GRB7, supporting the involvement of a KDM5B-TCF12-GRB7 regulatory network in HER2 modulation. Functionally, miR-770-5p reversed EMT-associated phenotypic features and enhanced trastuzumab sensitivity. Clinically, reduced KDM5B expression was associated with improved distant metastasis-free survival in ER+/HER2-high breast cancer patients. Collectively, miR-770-5p functions as a nuclear-associated regulatory microRNA that modulates HER2 signaling through epigenetic regulation of KDM5B and associated downstream networks. These findings suggest a previously unrecognized regulatory mechanism contributing to trastuzumab response and provide potential therapeutic avenues for HER2-positive breast cancer. - Source: PubMed
Publication date: 2026/07/20
Noyan SenemGurdal HakanCan AlpGur Dedeoglu Bala